In this review, we demonstrate the evolving landscape of clinical investigation as researchers and clinicians attempt to address the important therapeutic needs of patients with myeloproliferative neoplasms.
Leslie Padrnos, MD
Advertisement
Articles by Leslie Padrnos, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Clears Manufacturing Concern Behind Rivoceranib/Camrelizumab CRL in HCC
2
FDA Approves Gedatolisib for HR+, HER2– PIK3CA Wild-Type Advanced Breast Cancer
3
Gedatolisib Approval in HR+/HER2- Breast Cancer May Be “Practice Changing”
4
Managing Gedatolisib IV Delivery and Toxicity Profiles in Breast Cancer
5